TILT Biotherapeutics Oy is led by a highly experienced team with decades of expertise in early-stage cancer therapeutics research and development. Based in Finland, the company also operates a wholly owned U.S. subsidiary and has established a dedicated new spin-out entity TiltBio Inc to drive the later-stage development of its lead asset, TILT-123.
TiltBio Inc
The U.S. team contributes complimentary industry expertise from both Europe and the United States to drive the progression of the lead asset into late-stage development.
These are the principles that guide our work:
Board of Directors
The Board includes leading authorities and serial entrepreneurs in the life sciences, legal, financial, and pharmaceutical fields. The board is chaired by Arto Linnervuo.
Scientific Advisors
TILT’s scientific and clinical advisors include prominent clinicians and researchers from cancer-focused institutions across Europe and the U.S. In addition, the company holds indication specific advisory boards.
